AstraZeneca, SAS partnership to boost delivery of medicines via AI

AstraZeneca has appointed AI and analytics software company SAS to provide cloud-based software solutions with an aim to boost efficiency and automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

SAS will support the redesign of clinical and patient data flow by delivering analytics and AI, managing changing trial designs in a fast-evolving regulatory environment, enabling data re-use and helping accelerate reporting and submission timelines. It will also deliver increased capacity, automation, interoperability and flexibility to bring in and analyse diver and novel patient data sources (including those coming from wearables, sensors and precision medicine) as part of the submissions process.

This will be achieved by supporting the analysis and reporting phases with SAS Life Science Analytics Framework and SAS Viya, a cloud-based industry platform enabling swift decision-making. The SAS and AstraZeneca partnership will enable teams across the organisation to collaborate and increase clinical research innovation.

Christopher J Miller, VP Biometrics at AstraZeneca, said, “This partnership with SAS supports the transformation of how we use clinical data to support our patient-centric approach and focus on getting medicines to patients faster than ever before. It will also allow us to introduce new ways of working and embrace new technologies and trial models to accelerate our portfolio.”

“We pay attention to the technology and the advancements in AI, and we thrive on thinking through how our technology, blended with AstraZeneca’s expertise and insight, can create new medical solutions for their customers,” Brian Harris, SAS Executive Vice President and Chief Technology Officer, said.

Image credit: iStock.com/metamorworks